GlassScriptPhysician profile
Ronald W Hugar
NPI 1952475451
$2,718.81
in general payments reported to CMS, 2019-2025
15 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $260 · 2021: $91.10 · 2022: $627 · 2023: $318 · 2024: $241 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,564.86 | 2019-2025 | Grafix Pl, Grafix, Stravix |
| Osiris Therapeutics INC. | $368.77 | 2019 | |
| Stryker Corporation | $246.55 | 2020-2025 | Fixos, Variax, Pangea |
| Alafair Biosciences, INC. | $177.25 | 2024 | Versawrap |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $94.61 | 2022 | |
| Fusion Orthopedics USA, LLC | $47.05 | 2024 | |
| Horizon Therapeutics Plc | $37.07 | 2019 | |
| Treace Medical Concepts, INC. | $35.86 | 2025 | |
| Polynovo North America LLC | $28.41 | 2022-2025 | Novosorb Btm |
| Merck Sharp & Dohme LLC | $25.35 | 2019 | |
| Paratek Pharmaceuticals, INC. | $24.87 | 2021 | |
| Organogenesis INC. | $22.47 | 2020 | |
| Bioventus LLC | $16.71 | 2023 | Exogen Ultrasound Bone Healing System |
| Fidia Pharma USA INC. | $16.34 | 2024 | Triluron, Hymovis, Hyalgan |
| Acera Surgical, INC. | $12.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Hugar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.